Shared Resource 09: Leukemia Tissue Bank (LTBSR)

PROJECT SUMMARY – LEUKEMIA TISSUE BANK SHARED RESOURCE (LTBSR) The LTBSR is a longstanding biobank, established in 1997, that procures, processes, and stores biologic material from consenting patients with hematologic diseases. The LTBSR procures samples in two ways: 1) via a general biobanking protocol for future research; and 2) via specific clinical research protocols with special collection needs. The major services of the LTBSR are consenting patients, procuring samples (e.g., blood, bone marrow, and leukapheresis products) as directed by the general or a specific IRB protocol, assessing sample quality, providing fresh samples to investigators or processing them for storage, providing an oversight process for use of samples and data, and delivering samples and data to approved recipients. Investigators receive samples identified phenotypically or genetically, along with clinical data and available pathology data (including standard of care immunophenotyping and genetic sequencing panels). During the current cycle, Dr. Lapo Alinari (LR) replaced the prior LTBSR Director (David Lucas, who moved from Columbus), and Dr. Robert Baiocchi (LR) replaced Dr. Clara Bloomfield (LR) as the Senior Faculty Advisor. The Specific Aims of the LTBSR are to: 1) consent subjects and procure samples from patients with hematologic diseases; 2) uniformly process, characterize and store biospecimens using state-of-the art procedures; and 3) provide biospecimens with associated clinical, pathological and genomic data to OSUCCC researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. Over the current grant cycle, the LTBSR has supported 67 investigators (75% OSUCCC members) and all five of the OSUCCC research programs, 45 publications (11 > 10 impact factor) and 19 NCI grants, including 1 K12, 1 K22, 1 K23, 1 P01, 13 R01s, and 2 R35s. The OSUCCC has recently made a commitment to substantially increase samples obtained by lymph node sampling from lymphoma patients. In addition, the LTBSR has expanded services for collecting discarded normal hipbone from replacement surgeries as a source of marrow stromal cells and umbilical cord blood as a source of CD34+ hematopoietic stem cells. In the next funding cycle, the LTBSR will continue to expand its breadth of tissue procurement services, addressing the OSUCCC research priorities of immuno-oncology, translational genomics, and cancer prevention and survivorship. The annual budget of the LTBSR is $664,631, yet the CCSG request is $70,451. Thus, the LTBSR leverages extensive institutional support and seeks only 10.6% support from CCSG funds.